RGNX: REGENXBIO Inc.
Performance
RGNX -28.01%
Watchlist
Select an item
Summary
RGNX at a glance
RGNX returned -28.01% over the past year and -26.99% a year over five years. Its worst drop in that year was -64.64%, smaller than 9% of stocks on Redstone, and its Sharpe ratio of 0.09 beats 31% of stocks on Redstone. It pays no dividends.
Current Drawdown
-49.50%
Rolling Volatility
70.04%
Actions
Metrics
Risk Indicators
Alpha-8.33%
Beta1.70x
Sharpe0.09
Sortino0.12
Omega1.02
Calmar-0.43
Martin0.21
Profile
About RGNX
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $533M
- Listed
- Sep 2015
- Employees
- 371
- Headquarters
- Rockville, MD
- Website
- regenxbio.com
Comparisons